Hexagon Nutrition disclosed on August 18, 2026, that its Joint Managing Director and promoter, Dr. Nikhil Kelkar, acquired 16,400 equity shares in the company through the open market. The acquisition took place on August 17, 2026, increasing his total holding to 2,12,32,468 shares.

The purchase raises Dr. Kelkar’s stake in Hexagon Nutrition to 17.27% of the total voting capital, up from 17.26% prior to the transaction. This represents an increase of 0.01 percentage points in his ownership interest.

Acquisition Details

The disclosure was filed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The details of the shareholding change are outlined below:

Dr. Kelkar holds no encumbered shares, warrants, or convertible securities in the company. The total diluted share/voting capital remains unchanged at 12,29,18,109 shares following this transaction.

What the Numbers Show

The acquisition reflects a marginal consolidation of promoter ownership. With no encumbrances reported against the newly acquired or existing shares, the move indicates a clean addition to the promoter group’s unpledged equity base. The total voting capital of the company remained static during the period, suggesting the increase in stake was purely due to secondary market purchases rather than any corporate action like buybacks or rights issues.

Hexagon Nutrition Limited reported a significant improvement in profitability for the first quarter of FY27, with consolidated net profit rising 25.1% year-on-year to ₹80.73 million. Revenue from operations expanded by 43.2% to ₹1,043.06 million, reflecting strong top-line momentum following the company’s initial public offering and listing in June 2026.

The financial performance was underpinned by a substantial increase in total income, which reached ₹1,063.84 million compared to ₹742.37 million in the corresponding quarter of the previous year. While cost of materials consumed increased to ₹670.86 million from ₹426.15 million, the company benefited from a favorable change in inventories of finished goods and work-in-progress, recording a credit of ₹98.37 million against a credit of ₹75.72 million in Q1FY26.

What the Numbers Show

EBITDA for Q1FY27 stood at ₹118.01 million, up from ₹100.60 million in Q1FY26, representing a 17.31% year-on-year growth. However, the EBITDA margin contracted to 11.31% from 13.81% in the prior year period. This divergence between top-line growth and margin expansion suggests that input cost inflation or mix shifts may be exerting pressure on operating leverage, even as volume or price gains drive overall revenue higher.

A notable divergence exists between the standalone and consolidated results regarding revenue growth. Standalone revenue rose 60% to ₹1,014.02 million, outpacing the consolidated growth rate of 43.2%. This suggests that inter-segment eliminations or lower growth rates in specific subsidiaries may be moderating the group-wide top-line expansion. Additionally, other income declined significantly quarter-on-quarter from ₹39.55 million to ₹20.78 million, indicating that the current quarter’s profit growth was primarily driven by core operational efficiencies rather than non-operating gains.

Operational Updates and Guidance

During the earnings call held on August 14, 2026, management provided detailed insights into the drivers behind the results. Chief Financial Officer Soman Jana explained that the gross margin contraction was primarily due to rising costs of critical raw materials and ocean freight, exacerbated by geopolitical tensions in West Asia. To mitigate this, the company has increased the maximum retail price (MRP) of certain branded products by 10% to 15%, with the impact expected to reflect in Q2FY27 margins.

Volume growth played a significant role in the top-line expansion, with volumes growing between 25% and 40% year-on-year across premix and branded segments. The company’s current order book stands at approximately ₹100 crore, predominantly comprising premix and ESG (therapeutic nutrition) orders, which are expected to be executed in Q2 and partly in Q3. This visibility supports management’s guidance for a 20% to 25% revenue growth trajectory for FY27.

Capacity utilization has improved to 47% blended, up from roughly 30% in the previous period. Utilization varies by facility, with Nashik operating at 55% to 60%, Chennai at 25% to 30%, and Tuticorin at 35% to 40%. The company plans to invest ₹25 crore to ₹30 crore in capex over the next 12 to 18 months for the redevelopment of its Nashik premix facility, funded largely through long-term bank borrowing.

Segment Performance and Strategy

The branded nutrition segment continues to gain share, contributing approximately 28% of total revenue in Q1FY27, up from 18% historically. Dr. Nikhil Kelkar, Joint Managing Director, highlighted that the branded segment is expected to reach 35% of total revenue within the next couple of years, driven by expansion into Tier 2 and Tier 3 cities and increased digital marketing efforts. PentaSure remains the flagship brand, while newer brands like PediaGold and Obesigo are being scaled.

Exports remain a key pillar, with the company serving customers in over 70 countries. West Asia contributes less than 20% of total exports, limiting the impact of regional geopolitical issues. The top five export countries account for 25% to 40% of export revenue. The company is also focusing on expanding its presence in Central Asia, Africa, Europe, and North America.

Corporate Governance and Strategic Updates

The Board of Directors, meeting on August 12, 2026, recommended a final dividend of ₹0.30 per equity share of face value ₹1 each for the financial year ended March 31, 2026. The dividend is subject to shareholder approval at the 33rd Annual General Meeting scheduled for September 22, 2026. The record date for determining eligibility has been fixed as September 15, 2026.

In a move to strengthen its leadership team, the Board appointed Mr. Raghunath Sawant as Additional Executive Director with effect from August 12, 2026. Mr. Sawant, who has been associated with the company since July 2022, holds a Diploma in Food Technology. The Board also recommended the re-appointment of Mr. Arun Purushottam Kelkar as Chairman & Director.

Auditors S K Patodia & Associates LLP highlighted material uncertainties regarding two foreign subsidiaries, Hexagon Nutrition Proprietary Ltd (South Africa) and Hexagon Nutrition LLC (Uzbekistan), which reflect a net liability position due to historical accumulated losses. The holding company has committed to providing unconditional financial support to ensure their going concern status.